After the second large promotional jump on Friday, yesterday HEME crashed down by 21.67% on a volume of 20.35 million shares, or eight times the average for the pink sheets stock. After $10,000 have been paid for HEME’s appreciation at the end of September, the next portion of alerts, sent out on Friday, was supposedly for free.
The share price reacted, but the company’s attempts to concur the stock market also over countless press releases were not convincing. It looks like HEME’s intended future product is a so called neural communicator that will allow disabled individuals send neural signals to remotely control the functions of a computer or mobile equipment.
Two sentences in the company’s latest 10-Q have been devoted to that revolutionary technology: “Healthmed is entering into the beta stage of software testing of an application that allows remote access between the Apple iPad and a stationary PC. This software will allow healthcare professionals to be mobile and provide convenience for notes and records”.
After traders were not so convinced of the uniqueness of that planned product and of its ability to generate sales as long as it is developed at some time in the future, the company’s new management and new IR&PR firm (announced also at the end of September) can now hope that finally some big institutional investors will see some value in their planned new business and will provide them with some cash.
Because, as we previously reported, HEME is in urgent need of it. For the first six months of the year, HEME managed to spend the $8,073 they had and was left at the end of June with $52 in the bank, with which over $300,000 in debts had to be repaid.
